Author: Bharati, Joyita; Rathi, Manish; Ramachandran, Raja; Sharma, Aman; Nada, Ritambhra; Kohli, Harbir S.
Title: Managing Active Iupus Nephritis During COVID-19 Pandemic Cord-id: rb07ihld Document date: 2021_2_16
ID: rb07ihld
Snippet: India is seeing a rapid rise in coronavirus disease-2019 (COVID-19). Immunosuppression is a possible risk factor for severe COVID-19, although their exact interaction is unclear. A total of 13 cases with active lupus nephritis (LN, with or without extra-renal manifestations) were managed with intense immunosuppression between January 2020 and June 2020 during the COVID-19 pandemic at our center. There were no other comorbidities in any patient. All patients received hydroxychloroquine as a part
Document: India is seeing a rapid rise in coronavirus disease-2019 (COVID-19). Immunosuppression is a possible risk factor for severe COVID-19, although their exact interaction is unclear. A total of 13 cases with active lupus nephritis (LN, with or without extra-renal manifestations) were managed with intense immunosuppression between January 2020 and June 2020 during the COVID-19 pandemic at our center. There were no other comorbidities in any patient. All patients received hydroxychloroquine as a part of standard of care. Vigorous precautionary measures were taken for preventing infection in all. One patient developed acute respiratory distress syndrome but was tested negative for COVID-19. None of the other 12 patients developed symptoms suggestive of COVID-19. We report safe management of patients with active LN with intense immunosuppression along with vigorous precautions amidst the COVID-19 pandemic. The role of hydroxychloroquine along with timely precautions needs to be further explored as protective measures against COVID-19 among systemic lupus erythematosus patients.
Search related documents:
Co phrase search for related documents- active case and ln lupus nephritis: 1
- active case and ln patient: 1
- active case and lung disease: 1, 2
- active case and lupus nephritis: 1
- acute respiratory distress and lung characterize: 1, 2
- acute respiratory distress and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute respiratory distress and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute respiratory distress and lupus nephritis: 1, 2
- ln lupus nephritis and ln patient: 1
- ln lupus nephritis and lung disease: 1, 2
- ln lupus nephritis and lupus erythematosus: 1, 2, 3, 4, 5, 6
- ln lupus nephritis and lupus nephritis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- ln patient and lupus nephritis: 1
- lung disease and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- lung disease and lupus nephritis: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date